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Androgen Receptor YAC Transgenic Mice
Recapitulate SBMA Motor Neuronopathy and Implicate
VEGF164 in the Motor Neuron Degeneration
androgen insensitivity in affected males (Arbizu et al.,
1983). The finding of androgen insensitivity, together
with the X-linked pattern of inheritance, suggested the
androgen receptor (AR) gene as the potential cause of
SBMA. While a polymorphic CAG repeat in the first exon
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A useful approach for understanding polyglutamine
neurodegeneration has been to develop animal modelsX-linked spinal and bulbar muscular atrophy (SBMA)
of these diseases (reviewed in Bates et al., 1997; Lin etis an inherited neuromuscular disorder characterized
al., 1999). Mouse models have been particularly helpfulby lower motor neuron degeneration. SBMA is caused
in elucidating the basis of SBMA, as they have indicatedby polyglutamine repeat expansions in the androgen
that expression of full-length AR protein is necessaryreceptor (AR). To determine the basis of AR polyglu-
to properly recapitulate the motor neuron degenerationtamine neurotoxicity, we introduced human AR yeast
(Abel et al., 2001; Adachi et al., 2001; McManamny etartificial chromosomes carrying either 20 or 100 CAGs
al., 2002). Indeed, one recent transgenic mouse studyinto mouse embryonic stem cells. The AR100 trans-
demonstrated that mutant AR protein must bind ligandgenic mice developed a late-onset, gradually progres-
and then undergo nuclear translocation to produce neu-sive neuromuscular phenotype accompanied by motor
rodegeneration (Katsuno et al., 2002), indicating that theneuron degeneration, indicating striking recapitula-
nucleus is likely the key site of molecular pathology.tion of the human disease. We then tested the hypothe-
While the advances brought by such studies are signifi-sis that polyglutamine-expanded AR interferes with
cant, certain aspects of these models are lacking, soCREB binding protein (CBP)-mediated transcription of
important questions as to the mechanism of pathogene-vascular endothelial growth factor (VEGF) and ob-
sis remain. For example, none of the SBMA mouse mod-served altered CBP-AR binding and VEGF reduction
els generated to date have expressed the full-lengthin AR100 mice. We found that mutant AR-induced
AR protein under control of its endogenous regulatorydeath of motor neuron-like cells could be rescued by
elements. Furthermore, while it is likely that polygluta-VEGF. Our results suggest that SBMA motor neu-
mine-expanded AR exerts toxicity in the nucleus, theronopathy involves altered expression of VEGF, con-
mechanisms and pathways remain undefined.sistent with a role for VEGF as a neurotrophic/survival
To develop a truly representative model of SBMA thatfactor in motor neuron disease.
would address these issues, we chose to generate a
yeast artificial chromosome (YAC) transgenic mouse
Introduction model of SBMA with 100 CAG repeats. The “AR100”
transgenic mice developed a neuromuscular phenotype
X-linked spinal and bulbar muscular atrophy (SBMA, accompanied by degeneration of motor neurons in the
Kennedy’s disease) is a rare neuromuscular disorder anterior horn, supporting the conclusion that they suffer
characterized by adult-onset proximal muscle weak- from a motor neuronopathy. As previous studies of
ness due to lower motor neuron degeneration (Kennedy SBMA have suggested that polyglutamine-expanded
et al., 1968; Ringel et al., 1978). As the disease pro- AR might be interfering with the function of the transcrip-
gresses, patients develop dysarthria and dysphagia, tional coactivator CREB binding protein (CBP) (Mc-
representing the bulbar component of the phenotype Campbell et al., 2000), we determined if an aberrant
and accounting for the mortality in this disorder. Since interaction exists between CBP and AR and observed
SBMA is strictly a lower motor neuron disease, patients increased binding as a function of glutamine tract length.
display muscle weakness, flaccidity, and atrophy, but Although CBP is a general transcription cofactor, one
do not manifest spasticity or hyperreflexia. SBMA exhib- target of CBP gene expression regulation that plays an
its an X-linked pattern of inheritance, with males show- important role in the maintenance of motor neuron
ing full expression of the disease phenotype. An interest- health and survival is vascular endothelial growth factor
ing and important clinical feature of SBMA is prominent (VEGF). Interestingly, previous studies have shown that
the VEGF promoter contains a hypoxia-response ele-
ment (HRE) in its promoter and that deletion of just this*Correspondence: laspada@u.washington.edu
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HRE is sufficient to produce motor neuron degeneration
in mice (Oosthuyse et al., 2001). The hypoxia-inducible
factor 1 (HIF-1) transcription factor complex cannot
drive the expression of genes containing HREs in their
promoters unless a coactivator such as CBP is first
recruited (Carrero et al., 2000; Dames et al., 2002; Freed-
man et al., 2002). We hypothesized that polyglutamine-
expanded AR could interfere with CBP-mediated activa-
tion of VEGF gene expression in motor neurons and
present in vitro as well as in vivo evidence that lower
motor neuron degeneration in SBMA may involve altered
expression of VEGF.
Results
Generation and Characterization of AR YAC
Transgenic Mice
To produce an accurate model of SBMA, we chose to
obtain a yeast artificial chromosome (YAC) containing
the 100 kb human AR gene. Characterization of a 450
kb YAC that contains the human AR gene has already
been described (La Spada et al., 1998). These studies
indicated that the AR gene is centrally located within
this YAC, making it likely that the regulatory elements
required for proper temporal and spatial expression
within the central nervous system (CNS) would be pres-
ent. To introduce an expanded CAG repeat into this
construct, we took advantage of the highly efficient ho-
mologous recombination machinery of yeast and, using
the pop-in/pop-out approach, obtained an AR YAC con-
struct carrying a properly targeted CAG100 repeat
(Sopher et al., 2000) (Figure 1A). Since microinjection of
Figure 1. Generation and Expression Analysis of the AR YAC Trans- YAC DNAs typically yields fragments of the full-length
genic Mice construct (La Spada et al., 1998), we chose to fuse YAC-
(A) Diagram of YAC constructs. A 450 kb YAC containing the human bearing yeast cells with embryonic stem (ES) cells (Jako-
androgen receptor (AR) gene was obtained, and the AR gene’s bovits et al., 1993). The integrity of selected ES cell
central location is shown. The control construct contains 20 CAGs clones was confirmed by PCR (data not shown). RT-
(AR20), while the experimental construct was retrofitted with a 100
PCR analysis of RNA isolated from differentiated ESCAG repeat stretch (AR100). Both include a neomycin resistance
cells revealed the presence of human AR transcript (datacassette (asterisk).
(B) AR transgene is expressed at the RNA level. Primers were de- not shown). The undifferentiated counterparts of these
signed that spanned intron 1 and permitted coamplification of en- selected ES cells were injected into C57BL/6J blasto-
dogenous mouse AR (mAR) mRNA and human AR (hAR) transgene cysts to yield chimeric mice. Germline transmission from
mRNA. ApaI digestion yields two smaller fragments for hAR but unique ES cell clones subsequently gave rise to different
leaves mAR uncut, thereby allowing quantitative comparison. Re-
AR YAC CAG20 (AR20) and AR YAC CAG100 (AR100)sults of a representative RT-PCR experiment are shown: L, 100 bp
founders, permitting the establishment of four indepen-ladder; 1, DNA control; 2, human prostate RNA; 3, water control
(RT); 4, water control (RT); 5, AR20 brain RNA (RT); 6, AR20 dent transgenic lines (Table 1).
brain RNA (RT); 7, transgene-negative brain RNA (RT); 8, trans- To determine the level of expression of the human AR
gene-negative brain RNA (RT). transgene in each AR20 and AR100 transgenic line, RT-
(C) Full-length AR protein is expressed from the YAC transgene. PCR analysis was performed on brain RNAs from trans-
Protein was isolated from transiently transfected HEK293T cells or
gene-positive and control individuals (Figure 1B). Thisfrom mouse liver and then immunoblotted with antibody H-280. The
analysis indicated that human AR transgene levels in alltwo lanes on the left correspond to HEK293T cells transfected with
either an AR20 expression construct (AR20 ctrl) or an expanded
AR125 expression construct (AR125 ctrl). AR20 migrates at 110
kDa, while AR125 migrates at 130 kDa. The five lanes on the right
correspond to liver lysates from a nontransgenic mouse (ntg); two as described for part (C). Although a crossreacting band comigrates
AR20 mice (AR20; line C3A on the left and line C9B on the right); at 125 kDa in ntg and AR20 samples, the greater intensity of the
and two AR100 mice from line C25 (AR100). Intense bands migrating signal in the AR100 lanes is indicative of full-length AR100 protein
at 110 kDa and 125 kDa for AR20 and AR100 are indicated, expression. This result is corroborated with a different AR antibody
respectively, by the upper arrows. A crossreacting band at85 kDa (Supplemental Figure S1 at http://www.neuron.org/cgi/content/full/
(lower arrow) verifies equivalent loading. There is no immunoreactiv- 41/5/687/DC1). While no immunoreactivity is observed in the stack-
ity in the stacking area (bracketed with asterisk). ing portion of the gel (bracket; one asterisk), faint immunoreactivity
(D) Full-length AR protein is detected as a soluble monomer both is apparent in the left AR100 lane at the top of the separating gel
in AR20 and AR100 transgenic mice in the CNS. Protein was isolated (bracket; two asterisks) and may be consistent with microaggre-
from transiently transfected HEK293T cells or from mouse brain and gates or oligomers. Immunoblot analysis of nuclear fractions yielded
then immunoblotted with antibody H-280. The lanes and arrows are similar results (data not shown).
Androgen Receptor YAC SBMA Mice with Altered VEGF
689
attempting to walk (Supplemental Movie S1 at http://Table 1. Summary of AR YAC Transgenic Lines
www.neuron.org/cgi/content/full/41/5/687/DC1). The
Expression Level AR100 mice also show early mortality, dying of unknown
(Relative to
causes or requiring euthanasia due to inanition at 15–24Transgenic Line Repeat Length Endogenous mAR)a
months of age, depending upon expression level (Figure
C3A CAG 20 0.3 2D). The AR20 mice, however, never developed a notice-
C9B CAG 20 1.0 able phenotype, nor did they display decreased survival.
C25 CAG 100 0.8
A unique feature of SBMA is its X-linked pattern ofC32 CAG 100 0.6
inheritance and sex-limited expression. To compare dis-
a RT-PCR analysis comparing the human AR transgene level to the ease progression in AR100 transgenic mice, we created
mouse endogenous AR level was performed as described in Experi-
a rating scale to grade the severity of the phenotype.mental Procedures. All samples were run in triplicate, and the aver-
While male C25 AR100 and male C32 AR100 mice pro-age of the three runs was rounded to the nearest 0.1.
gress through all three stages in the course of 1–2 years,
female C25 AR100 and female C32 AR100 mice never
show the full expression of the disease phenotype (Table
four lines are close to one another and are relatively 2). Thus, in the case of our SBMA mouse model, the
physiological, varying from 30%–100% of endogenous expression of the phenotype is gender dependent. Fe-
levels (Table 1). We performed Western blot analysis to male AR100 mice are mildly affected, however, as they
verify the expression of full-length human AR protein, are often smaller in size and weight, and in the case of
first in liver (Figure 1C) and then in brain (Figure 1D). the higher-expressing C25 line, occasionally show signs
Soluble monomeric AR protein was readily detectable of hindlimb atrophy beyond 2 years of age. The presence
in both of these tissues, regardless of the length of of a phenotype in female AR100 mice is not unexpected,
the polyglutamine repeat expansion, and was confirmed as many female SBMA carriers complain of muscle
with another antibody (Supplementary Figure S1 at cramps and weakness and occasionally develop minor
http://www.neuron.org/cgi/content/full/41/5/687/ neuromuscular abnormalities (Sobue et al., 1993; Mari-
DC1). Inspection of the stacking portions of the brain otti et al., 2000).
immunoblots revealed no evidence for typical aggre- In addition to charting the course of the neurological
gates in AR100 mice, although increased immunostain- phenotype by examination and visual inspection, we
ing at the top of separating gels was occasionally noted determined when AR100 mice first show behavioral ab-
(Figure 1D). We then immunostained sections from the normalities in gait and muscle strength testing para-
central nervous system (CNS) of transgenic and non- digms. While footprint analysis performed on nontrans-
transgenic mice to determine the pattern of expression genic and C25 AR100 mice at 6.5 months revealed
of the transgene. We observed marked expression of similar stride lengths (p  0.55), analysis at 11 months
human AR protein in the anterior horn cells of the spinal indicated that significant differences in stride length
cord, cranial nerve nuclei V (motor) and VII in the brain- measurements exist prior to the development of visible
stem, the cortex, the hypothalamus, and the olfactory gait abnormalities (p  0.05) (Figure 2E). To evaluate
bulb (presented later in Figure 4). No expression of hu- muscle strength, we subjected C25 AR100 mice and
man AR was observed in motor layer V of the cortex, their nontransgenic littermates to the “hanging wire”
nor in the cerebellum or hippocampus (data not shown). test (Crawley, 1999). While AR100 mice were not able
to hold their bodies up on an inverted cage lid as long
as age-matched littermates at 6.5 months (Figure 2F),AR YAC CAG100 Mice Exhibit a Progressive
this performance difference was not significant (p Motor Deficit
0.30). By 11 months of age, however, control littermatesWe evaluated the health and behavioral phenotype of
displayed “latency to fall” times that were nearly 3.5AR YAC transgenic mice and noted abnormalities in
times longer than AR100 mice (p  0.01) (Figure 2F).both AR100 lines. In the higher-expressing AR100 C25
Thus, behavioral abnormalities in gait and muscleline, the first sign of a phenotypic difference is growth
strength appear in the AR100 mice just before they showretardation beginning at about 8 months of age. By 10
a phenotype. Similar studies performed on AR20 malemonths of age, the difference in body size and weight
mice revealed performance results comparable to thatis readily apparent (Figure 2A). Weight loss is soon ac-
of controls (data not shown).companied by proximal muscle weakness, producing a
curvature of the spine that gives the AR100 mice an
obvious kyphotic appearance (Figure 2B). At 14 months AR YAC CAG100 Mice Develop
a Motor Neuronopathyof age, AR100 mice from the C25 line display a visible
phenotype of impaired mobility, difficulty with walking, While the visible and behavioral phenotype of the AR
YAC CAG100 mice resembles the clinical disease inand marked hindlimb atrophy. Footprint analysis of such
individuals illustrates a profound impairment in their SBMA patients, a key question is whether the AR100
mice show pathological changes consistent with motorability to ambulate (Figure 2C). Individuals from the
AR100 C32 line show a similar phenotype and natural neuronopathy. To address this question, we performed
hematoxylin and eosin (H&E) staining of quadricepshistory of progression with everything delayed (Table
2), presumably due to the lower expression level of AR muscle sections obtained from AR100 mice and age-
matched controls (Figures 3A and 3B). H&E staining ofCAG100 protein. Ultimately, many of the AR100 mice
develop a hindlimb paralysis, as evidenced by dragging such muscle sections revealed marked histopathology
in the AR100 mice. To determine the nature of the muscleof their hindpaws and hindlimbs along the ground when
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Figure 2. Visible and Behavioral Phenotype
of the AR YAC CAG100 Mice
(A) Representative photograph of a 10-month-
old AR100 line C25 transgenic mouse (left)
and its age-matched nontransgenic litter-
mate (right) reveals an obvious difference in
size and weight.
(B) Representative photograph of a 14-month-
old AR100 line C25 transgenic mouse illus-
trates the kyphosis that develops as the mice
age and their muscle weakness progresses.
(C) Footprint analysis performed on a 14-
month-old nontransgenic littermate control
shows a normal stride (left), while footprint
analysis of a 14-month-old AR100 line C25
transgenic mouse indicates gait impairment
(right). Blue poster paints were applied to the
hindpaws, and orange poster paints were ap-
plied to the forepaws.
(D) AR100 mice display a reduction in life
span. Kaplan-Meier plot shows the decreased
survival of AR100 line C25 mice (n  13),
AR100 line C32 mice (n 13), and the normal
life spans of wild-type (n 16) and AR20 mice
(n  16).
(E) AR 100 mice show decreased stride length
prior to visible gait impairment. Groups of
AR100 line C25 mice and nontransgenic lit-
termates (n  6–8/group) were subjected to
footprint analysis, and mean stride lengths
were calculated and compared between the
two groups. By 11 months of age, the AR100
mice displayed significantly shorter stride
lengths.
(F) AR100 mice appear weaker than controls
in the hanging wire test. Groups of AR100 line
C25 mice and nontransgenic littermates (n 
6–8/group) were suspended from their cage
lids with forepaws and hindpaws gripping the
bars and the time until they fell measured.
While a slight trend in falling off more quickly
is noted in AR100 mice at 6.5 months of age,
the ability of AR100 mice to hang on to the
cage lid only becomes significantly impaired
at later ages.
pathology, we performed enzymatic staining. NADH- fibers (Figure 3F). NCAM-stained sections from non-
transgenic controls were negative for sarcoplasmic ex-stained sections from control mice showed a scattered
distribution of type II muscle fibers (Figure 3C), while pression (Figure 3E). The NADH and NCAM staining data
strongly support the conclusion that AR100 mice areNADH staining of AR100 muscle sections revealed large
areas of fiber type grouping (Figure 3D). Immunostaining suffering muscle atrophy due to denervation. To assess
whether AR100 mice display motor neuron degenera-with an antibody directed against neural cell adhesion
molecule (NCAM), a protein known to be upregulated tion, we reviewed lumbar spinal cord sections stained
with a basic dye (Richardson’s). While we noted theduring muscle renervation (Gosztonyi et al., 2001; Mar-
bini et al., 2002), revealed numerous positively staining presence of six to eight basophilic cell bodies of healthy
Table 2. Summary of Phenotype Data for the AR100 Transgenic Mice
Age of Onset of Visible Gait Age of Onset of Severe
Age of Onset of Decreased Impairment & Hindlimb Hindlimb Atrophy, Paralysis, &
Transgenic Line and Sex Size & Weighta (Stage 1) Atrophy (Stage 2) Immobility (Stage 3)
C25-Male 8 months 13 months 17 months
C25-Female 17 months 26 months –
C32-Male 12 months 18 months 22 months
C32-Female 22 months – –
All ages given are  1 month. The AR20 lines C3A and C9B are not included in this table, since they do not develop a phenotype, and they
live out a normal lifespan. “–” indicates “not observed.”
a A mouse was judged to be of decreased size and weight when its nontransgenic littermates were 25% larger by length and mass.
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Figure 3. AR YAC CAG100 Mice Develop a
Motor Neuronopathy
(A–F) Muscle histopathology in the AR YAC
SBMA mouse model. Quadriceps muscle
sections from nontransgenic littermate con-
trols (A, C, and E) or from AR100 transgenic
mice (B, D, and F) were stained with hematox-
ylin and eosin (H&E) (A and B); for NADH (C
and D); or with an anti-NCAM antibody (E and
F). While the H&E staining of nontransgenic
muscle shows normal angulated fibers of
similar shape and size with peripheral nuclei
(A), H&E staining of a 16-month-old AR100
line C25 individual reveals marked variation
in fiber size, with intermixed, shrunken, and
hypertrophied fibers (B). In addition, the nu-
clei are centrally located with extensive re-
placement of muscle by fibrous tissue and
fat. NADH staining of nontransgenic muscle
shows dark-staining fibers distributed among
light-staining fibers in no particular pattern
(C), but NADH staining of muscle from a 14-
month-old AR100 line C25 mouse reveals
dark-staining fibers grouped together (D). No
appreciable staining with an anti-NCAM anti-
body is observed in nontransgenic muscle
(E), while anti-NCAM staining of AR100 line
C25 muscle from a 14-month-old mouse indi-
cates that a number of muscle fibers are posi-
tive (F), consistent with renervation.
(G and H) Spinal cord pathology in the AR
YAC SBMA mouse model. Sets of 20M lum-
bar spinal cord sections from a nontransgenic
littermate control and a 16-month-old AR 100
line C25 mouse were stained with a basic
dye stain (Richardson’s) and the ventrolateral
columns serially evaluated. Here we see a
representative set of images. While the non-
transgenic control (G) exhibits numerous
healthy motor neurons with pronounced cy-
tosolic basophilia (arrows), the AR100 indi-
vidual (H) shows a decreased number of mo-
tor neurons (arrow). Note the lack of cytosolic
basophilia in panel (H) and the presence of a
degenerating motor neuron (asterisk).
motor neurons in the ventrolateral columns of control in spinal cord motor neurons, sensory neurons, or
sections (Figure 3G), we observed no more than three interneurons in AR100 mice. While ultrastructural analy-
or four motor neuron cell bodies in AR100 mice (Figure sis of AR100 motor neurons corroborated this absence
3H). In addition to a relative paucity of motor neurons, of nuclear aggregates (data not shown), these studies
the cell bodies of the remaining motor neurons were do not exclude the possible presence of “microaggre-
pale by comparison and appeared shrunken, suggesting gates.” Although we did not observe nuclear inclusions
that they were degenerating (Figure 3H). Taken together, in motor neurons, we did detect punctate staining in the
these findings indicate that AR YAC CAG100 transgenic nuclei of spinal cord astrocytes in AR100 mice but not
mice recapitulate the muscle atrophy/motor neuron de- age-matched nontransgenic or AR20 controls (Figures
generation phenotype seen in SBMA. 4D–4F), suggesting that AR100 nuclear aggregates form
in nonneuronal cells. In CNS sections from the AR100
mice, we noted the presence of punctate nuclear aggre-Polyglutamine-Expanded AR Protein Accumulates
gates in the dorsal lateral hypothalamus and tectumin the Nucleus but Does Not Form Nuclear
(Figure 4G; data not shown). Neuropathology examina-Aggregates in Pathologically Affected Regions
tion of these regions failed to indicate any degenerativeTo determine the subcellular localization of polygluta-
changes. Immunostaining of brainstem sections, how-mine-expanded AR protein, we performed immunohis-
ever, revealed diffuse nuclear staining of neurons thattochemistry on CNS sections using AR-specific antibod-
comprise the motor nucleus of cranial nerve V and cra-ies. Immunostaining of motor neurons revealed only
nial nerve VII (Figure 4H; data not shown). We also sur-faint nuclear staining in AR20 controls while showing
veyed other nonneuronal tissues and observed obviousdramatic nuclear accumulation of human AR protein in
nuclear inclusions in AR100 muscle and liver (Figure 4I;AR100 mice (Figures 4A–4C). However, in no case did
we detect the formation of classic nuclear aggregates Supplemental Figure S2 at http://www.neuron.org/cgi/
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Figure 4. Subcellular Localization of AR Pro-
tein and NI Distribution in the SBMA Mice
(A–F) Confocal immunostaining analysis of
spinal cord sections. Fourteen-month-old
AR100 line C25 mice (A and D), 14-month-
old AR20 line C9B mice (B and E), and age-
matched nontransgenic controls (C and F)
were studied by obtaining 40 M-thick lum-
bar spinal cord sections and immunostaining
with antibody H-280 (red) in combination with
DAPI (blue). Human AR protein accumulates
in AR100 motor neuron nuclei to yield an in-
tense but nonetheless diffuse, nonaggre-
gated staining pattern (A). In AR20 motor neu-
ron nuclei, the nuclear staining is faint at best
(B), and no appreciable staining is observed
in nontransgenic motor neuron nuclei (C).
Dense, punctate anti-AR staining is however
observed in the nuclei of astrocytes in the
lumbar spinal cord of the same AR100 mouse
(D), but neither aggregates nor appreciable
staining of astrocytes is seen in AR20 or non-
transgenic controls (E and F).
(G-I) Immunodetection of human AR protein
in different regions of the AR100 mice. While
NIs are prominent and obvious in neurons in
the dorsal lateral hypothalamus of this 14-
month-old AR100 mouse (G), diffuse nuclear
staining is instead observed in the brainstem
motor nucleus of cranial nerve V (H). Outside
the CNS, nuclear aggregates can be detected
in a variety of tissues, including muscle (I)
and liver (Supplemental Figure S2 at http://
www.neuron.org/cgi/content/full/41/5/687/
DC1).
The scale bar for each panel is 25 m.
content/full/41/5/687/DC1). Thus, spinal cord and brain- resultant pull-down lysates with an anti-AR antibody
and observed increasing amounts of AR in the pull-stem neurons affected in SBMA stain diffusely and lack
classic nuclear aggregates in the AR100 mice, while downs, with lengthening of the glutamine tract (Figure
5A). We then performed coimmunoprecipitation of CBPnuclear aggregates instead form in unaffected neurons
and in cell types of nonneuronal origin in this mouse and AR on spinal cord lysates from nontransgenic,
AR20, and AR100 mice and noted that anti-AR immu-model.
noblots of CBP pull-down material yielded the most
intense signals for the AR100 samples (Figure 5B). AnPolyglutamine-Expanded AR Interferes with CBP-
increase in the binding of CBP by AR in a glutamineMediated Transcription of VEGF
length-dependent fashion supports the hypothesis ofThe nuclear localization of polyglutamine-expanded AR
CBP transcription interference.in motor neurons suggests that SBMA pathogenesis
Since deletion of a CBP-regulated promoter elementinvolves the nucleus. Indeed, nuclear translocation of
of the VEGF gene in mice is sufficient to produce motorAR mediated by ligand binding preceded AR polyglu-
neuron degeneration (Oosthuyse et al., 2001), we hy-tamine toxicity in two independent studies of SBMA
pothesized that downregulation of VEGF expression duemouse and fruit fly models (Katsuno et al., 2002; Takey-
to CBP transcription interference contributes to motorama et al., 2002). The fact that AR is a transcription
neuron degeneration in SBMA. To test this hypothesisfactor belonging to the steroid- thyroid hormone recep-
in our AR100 mouse model, we isolated spinal cordtor superfamily suggests that the nuclear process being
RNAs from presymptomatic AR100 mice and measuredaltered in SBMA could be transcription. One possible
VEGF expression levels using real-time RT-PCR analysismechanism of transcriptional dysregulation proposed
with the TaqMan approach (Livak et al., 1995). Withfor SBMA is interference with CBP, a transcription co-
primers designed to detect all three isoforms of VEGFactivator that remodels chromatin through its histone
(i.e., VEGF 120, VEGF 164, and VEGF 188), we observedacetyltransferase activity (Bannister and Kouzarides,
no significant difference between the AR100 mice and1996; Ogryzko et al., 1996). To determine if glutamine
age-matched nontransgenic controls at 6.5 months ofexpansion results in an altered interaction between CBP
age (Figure 6A). Similar results were obtained for SCA7and AR, we transfected AR expression constructs of
92Q transgenic mice that express mutant protein in thevarying glutamine lengths into HEK293T cells in the
spinal cord but do not show motor neuron degenerationpresence of the AR ligand dihydrotestosterone, and per-
(Garden et al., 2002). Interestingly, the expression levelformed coimmunoprecipitation on protein lysates from
HEK293T cells with an anti-CBP antibody. We probed of VEGF detected in the AR20 spinal cords was signifi-
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of controls. We then measured VEGF 164 levels in mice
at 11 months, just prior to the onset of visible hind limb
atrophy and gait impairment (Figure 6B). We observed
a further decrease in VEGF 164 message levels in AR100
mice at this age. Thus, RT-PCR analysis of VEGF 164
expression revealed a specific decrease in presymp-
tomatic AR100 mice.
To independently confirm the VEGF downregulation,
we chose to measure VEGF protein levels by ELISA. The
ELISA method employed an antibody that detects all
three VEGF isoforms. VEGF 188 is typically not present
in protein lysates, however, as it remains bound to the
extracellular matrix (Ferrara et al., 2003). ELISA mea-
surements performed on spinal cord lysates obtained
from 8-month-old nontransgenic, AR20, and AR100
mice showed a significant reduction in VEGF 120  164
levels in AR100 male mice and a significant increase in
VEGF 120  164 levels in AR20 male mice (Figure 6C).
We also measured VEGF 120  164 protein levels in
spinal cord lysates from female mice and observed no
meaningful changes (Figure 6C). The ELISA results thus
confirmed the VEGF 164 expression decreases ob-
served by real-time RT-PCR in the spinal cords of pre-
symptomatic AR100 SBMA mice.
To assess the biological significance of the VEGF 164
downregulation, we employed a well-established motor
neuron cell culture model of AR polyglutamine neurotox-Figure 5. Coimmunoprecipitation of AR by CBP Is Enhanced by
icity. A number of previous studies have shown thatPolyglutamine Tract Expansion Both In Vitro and In Vivo
transfection of AR expression constructs into MN-1 (mo-(A) HEK293T cells were transfected with empty vector, AR12, or
AR112 expression constructs. The top panel indicates the amount tor neuron-neuroblastoma hybrid) cells reproduces key
of AR protein expression in the cell lysates used for co-ip. After features of AR polyglutamine length-dependent pathol-
pull-down with a monoclonal anti-CBP antibody, we probed the ogy (Merry et al., 1998; McCampbell et al., 2000). As
resultant pull-down material with a polyclonal anti-CBP antibody
expression of full-length AR in MN-1 cells yields polyglu-and observed roughly equivalent amounts of CBP (middle panel).
tamine length-dependent cell death, we supplementedProbing of this immunoblot with antibody N-20 yielded the amounts
the culture media with VEGF 164 peptide and found thatof AR present in the CBP co-ip (bottom panel). Normalized quantifi-
cation of AR112 band intensities is shown. VEGF could protect AR112-expressing MN-1 cells from
(B) Spinal cord lysates from 11-month-old nontransgenic, AR20 cell death (Figure 6D). Furthermore, the ability of VEGF
C9B, and AR100 C25 male mice were subjected to co-ip with a 164 to rescue cell death in AR112-expressing MN-1 cells
monoclonal anti-CBP antibody. We probed the pull-down material
was dose dependent (Figure 6E). Since we had attrib-with a polyclonal anti-CBP antibody and with anti-AR antibody
uted the VEGF downregulation observed in our AR100N-441. Despite pulling down less CBP in the transgenic samples,
SBMA mice to CBP transcription interference, we co-an in vivo binding interaction with AR was evident and appeared
significantly stronger in AR100 spinal cord, as the ratio of AR:CBP transfected CBP and AR112 expression constructs into
in the AR100 sample was 50% higher than the AR20 sample. All MN-1 cells to determine if CBP overexpression could
co-ips were performed in triplicate on at least two samples per ge- also rescue AR112-mediated cell death. A marked re-
notype.
duction in cell death was indeed noted with CBP cotran-
sfection, and the extent of rescue correlated with the
level of CBP expression (Figure 6F). RT-PCR measure-cantly higher than that of the nontransgenic controls
ments of VEGF 164 levels in MN-1 cells cotransfected(p 0.01), reflecting the ability of AR to directly regulate
with CBP correspondingly revealed restoration of VEGFVEGF expression (Ruohola et al., 1999; Louissaint et al.,
gene expression (Figure 6F), supporting our hypothesis2002). Previous work on VEGF has indicated that the
that CBP transcription interference at the VEGF pro-functions of the three different isoforms of VEGF are
moter is a component of AR polyglutamine neurotoxicitynot interchangeable. Indeed, the VEGF 164 isoform was
in SBMA.shown to be expressed by motor neurons and to protect
motor neuron-like cells from various apoptotic insults,
suggesting that VEGF 164 possesses neurotrophic ac- Discussion
tivity (Oosthuyse et al., 2001). For these reasons, we
designed TaqMan primers and probe to specifically de- We have generated a YAC transgenic mouse model of
SBMA using the technique of yeast-ES cell fusion totect VEGF 164. When we performed real-time RT-PCR
analysis using the discriminating primers and probe, we insure that a 450 kb AR YAC with 100 CAGs is maintained
intact upon integration into the mouse genome. Becausenoted a marked decrease in the expression of VEGF 164
in the spinal cords of AR100 mice at 6.5 months (Figure we maintained the human AR gene in a genomic context
that provides over 150 kb of adjacent sequence both 56B). The VEGF 164 expression levels in AR20 mice and
2.5-month-old SCA7 92Q mice were comparable to that and 3 to the human AR gene, proper temporal and
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Figure 6. Role of VEGF 164 in Motor Neuron
Degeneration in AR100 Transgenic Mice and
in AR Polyglutamine Neurotoxicity in MN-1
Cells
(A) The results of real-time RT-PCR analysis
of VEGF message that gives rise to all three
VEGF isoforms is shown for sets of 6.5-
month-old nontransgenic, AR20 line C9B,
and AR100 line C25 mice along with 2.5-
month-old PrP-SCA7-c92Q mice (n  3–4/
group). Mean levels of VEGF expression are
comparable in the spinal cords of the non-
transgenic, SCA7 92Q, and AR100 mice (p 
0.37), but VEGF expression is higher in the
AR20 group (p  0.005).
(B) Real-time RT-PCR analysis of the VEGF
164 isoform in spinal cord. Here we see the
results of TaqMan real-time RT-PCR specifi-
cally directed to the VEGF 164 isoform. At 6.5
months (left), a significant decrease in VEGF
164 is noted in the AR100 spinal cord samples
(p  0.01) but not in AR20 or SCA7-92Q sam-
ples, suggesting that the decrease is polyglu-
tamine length-dependent and SBMA specific.
At 11 months (right), a further decrease in
VEGF 164 levels in AR100 spinal cord is noted
(p  0.005).
(C) ELISA measurement of VEGF 120  164.
Spinal cord lysates were prepared from sets
of male or female mice at 8 months of age
(n  3–4/group) and mean levels compared.
For 8-month-old male mice (left), a significant
increase in VEGF 120  164 is observed for
AR20 mice (p  0.05), likely reflecting AR-
driven upregulation. However, a significant
decrease in VEGF 120 164 is seen in AR100
mice (p 0.01). As AR100 overall VEGF levels
are normal (A) but VEGF 164 levels decreased
(B), this reduction likely represents a de-
crease in VEGF 164, especially since AR20
males exhibit elevated overall VEGF levels
but relatively unchanged VEGF 164 levels
(see [A] and [B] of this figure). For 8-month-
old female mice, no significant differences in
VEGF protein levels are noted (p  0.28).
(D) VEGF 164 rescues AR polyglutamine tox-
icity in motor neuron-like cells in culture.
MN-1 cells were transfected with CMV-AR
expression constructs or empty vector, and
the effect of VEGF164 supplementation upon
cell death was determined using a viability
assay. Significant rescue of AR polyglutamine
length-dependent cell death by VEGF 164 (10
ng / ml) was observed (p  0.01).
(E) VEGF 164 rescue of AR112-mediated cell
death is dose dependent. Cell viability was
assayed for MN-1 cells transfected with the
pcDNA3.1-AR112 expression construct at a
range of VEGF concentrations. Each 2-fold
increase in VEGF concentration yielded pro-
gressively greater survival (p  0.01).
(F) CBP overexpression rescues AR polyglu-
tamine neurotoxicity and upregulates VEGF
164 expression levels in MN-1 cells. We tested the ability of CBP cotransfection to counter AR polyglutamine neurotoxicity and found that
overexpression of CBP did mitigate AR112-induced MN-1 cell death (p  0.05). With increasing overexpression of CBP, significantly greater
reduction in AR polyglutamine neurotoxicity was noted (p  0.01). Real-time RT-PCR analysis of VEGF 164 levels (graph on right) performed
upon MN-1 cells cotransfected with AR112 and CBP at varying concentrations (0, 5, 30 ng/l) indicated that CBP overexpression could
overcome the suppression of VEGF gene expression by polyglutamine-expanded AR (p  0.05; p  0.0001). Note that the percent change in
VEGF 164 message levels are compared to VEGF 164 levels in MN-1 cells transfected with empty expression vector.
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spatial regulation of the AR gene is preserved. Another While certain aspects of disease pathogenesis have
been determined for SBMA, the molecular basis of ARimportant feature of our model is relatively physiological
levels of transgene expression, as RT-PCR analysis indi- polyglutamine neurotoxicity remains completely un-
known. AR is a transcription factor whose nuclear local-cated that our highest expressing AR20 and AR100
transgenic lines, respectively, produce human AR mes- ization is modulated by ligand binding (Simental et al.,
1991; Zhou et al., 1994, 1995). Recent studies in micesage equivalent to or at 80% of that of endogenous
mouse AR message. By generating AR YAC transgenic and fruit flies convincingly demonstrated that mutant
AR must bind ligand and translocate to the nucleus tomice in this way, we were successful at modeling key
features of SBMA, as independent lines of AR YAC CAG produce toxicity in SBMA (Katsuno et al., 2002; Takey-
ama et al., 2002). These findings explain why a dominant100 transgenic mice display a late-onset, gradually pro-
gressive phenotype of neurogenic proximal muscle atro- mutation is relatively harmless even in homozygous hu-
man females carrying AR polyglutamine expansionsphy. The age of onset in the AR100 C25 line occurs in
mid-adulthood and therefore parallels that of humans (Schmidt et al., 2002). The SBMA YAC mouse model
that we have generated also shows the strong gender(i.e., at 40% of maximal life span). The progressive
weakness and atrophy of the proximal hindlimbs are effect seen in the human disease (Table 2). The apparent
necessity of AR nuclear localization in SBMA and thehighly reminiscent of what is observed in human SBMA
patients. Indeed, SBMA patients can end up wheelchair fact that AR is a transcription factor suggest that AR
polyglutamine neurotoxicity may involve transcriptionalbound, and similarly, many AR100 mice rather dramati-
cally lose the ability to ambulate (Supplemental Movie S1 dysregulation. One line of investigation into the basis of
mutant AR toxicity has focused upon interference withat http://www.neuron.org/cgi/content/full/41/5/687/DC1).
Importantly, the pathology in the AR100 mice appears the function of the transcription coactivator CBP
(McCampbell et al., 2000). CBP was originally identifiedto be restricted to lower motor nerve units, suggesting
that the SBMA YAC model retains the cell type specific- as a cofactor for the transcription factor CREB and has
a tract of 18 glutamines near its carboxy terminus (Kwokity of the human condition, unlike previous AR trans-
genic mice (Abel et al., 2001; Adachi et al., 2001; McMa- et al., 1994). Glutamine tract-glutamine tract interactions
are often involved in productive binding of transcriptionnamny et al., 2002). For these reasons, we believe that
the AR100 transgenic mice strikingly recapitulate the factors to one another and subsequent transcription
activation. Thus, one theory of polyglutamine diseasehuman SBMA phenotype and thus make an ideal model
to evaluate the natural history of the illness and assess pathogenesis posits that expanded polyglutamine tracts
contained in different disease proteins interfere with thepotential therapeutic interventions.
One interesting aspect of our SBMA mouse model function of transcription factors containing glutamine
tracts or glutamine-rich regions and thereby disruptis the absence of NIs in pathologically affected motor
neurons of the spinal cord and brainstem. While expres- transcriptional processes to cause disease (Freiman and
Tjian, 2002). The basis of CBP transcription interferencesion of human AR protein localizes to the nucleus, we
did not detect nuclear aggregates in spinal cord motor remains unknown but has been suggested to involve
sequestration of CBP into nuclear aggregates or en-neurons but instead observed an intense but diffuse
nuclear staining (Figure 4). NIs were, however, observed hanced turnover of CBP secondary to induction of the
ubiquitin-proteasome pathway (McCampbell et al., 2000;in neurons of the dorsal lateral hypothalamus and the
tectum—regions not displaying degeneration in our Jiang et al., 2003). In the case of the Sp1 transcription
factor, a soluble phase interaction between polygluta-mice or typically associated with neuropathology in
SBMA. Accumulation of AR transgenic protein was not mine-expanded huntingtin and Sp1 may account for Sp1
transcription interference in HD (Dunah et al., 2002; Li etdetected in AR20 mice but instead was specific to
AR100 mice, suggesting that turnover of mutant AR is al., 2002). We tested the hypothesis of CBP transcription
interference by performing coimmunoprecipitations onimpaired. These findings suggest that polyglutamine-
expanded AR is toxic when present in the soluble phase HEK293T cells transfected with AR expression con-
structs and observed marked increases in CBP bindingand that, perhaps, the ability of hypothalamic and tec-
tum neurons to form aggregates renders mutant AR to polyglutamine-expanded AR. AR-CBP coimmuno-
precipitations performed on spinal cord lysates fromnontoxic. This observation is consistent with a SCA1
knockin mouse model that displayed a correlation be- AR100 male mice confirmed that the polyglutamine
length-dependent increase in AR-CBP binding occurstween neuronal vulnerability and increased solubility of
ataxin-1 with 154 glutamines (Watase et al., 2002). The in vivo.
One mechanism by which CBP transcription interfer-SCA1 knockin study revealed that the formation of NIs
in vulnerable neurons does occur but not until late in ence might result in SBMA motor neuron degeneration
stems from the striking finding that deletion of a CBP-the course of the disease. As our highest expressing
AR100 line produces human AR message at 80% of regulated element in the VEGF gene in mice is sufficient
to produce a spinal muscular atrophy-like phenotypethat of endogenous mouse message, it is possible that
an insufficient level of AR expression prevented obvious (Oosthuyse et al., 2001). In that study, a 35% reduction
of VEGF protein expression levels in normoxic spinalNI formation in motor neurons within the life span of
these mice. Although the absence of NIs in degenerating cord was documented by ELISA in mice homozygous
for deletion of the VEGF promoter HRE. As HIF-1 trans-and dying motor neurons in our SBMA mouse model
implies that NI formation is not required for polygluta- activation of HRE-driven gene expression requires re-
cruitment of CBP or p300 (Carrero et al., 2000; Damesmine neurotoxicity, the involvement of microaggregates
or polyglutamine-containing oligomers cannot be ex- et al., 2002; Freedman et al., 2002), we hypothesized
that increased binding of CBP by polyglutamine-cluded.
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expanded AR could interfere with its ability to coactivate whether conserved pathways relevant to motor neuron
HRE-dependent VEGF gene expression. We tested this health and survival exist and if such pathways operate
hypothesis by performing quantitative real-time RT-PCR in a wide range of motor neuron diseases. This study
analysis on RNA isolated from the spinal cords of pre- suggests that there is reason to believe that decreased
symptomatic AR100 mice. The mouse and human VEGF expression of VEGF or an inability to upregulate VEGF
genes are alternatively spliced to yield three or four in the face of injury, ischemia, or stress is a fundamental
different isoforms, respectively: VEGF 120/1, VEGF property of degenerating motor neurons. The initial evi-
164/5, VEGF 188/9, and -/VEGF206 (Ferrara et al., 2003). dence for this emerging view came from an unexpected
We began by using a TaqMan probe and PCR primers finding of motor neuron disease in mice lacking just
that spanned a portion of the VEGF gene included in all the HRE sequence in the promoter of the VEGF gene
three murine isoforms and found no difference between (Oosthuyse et al., 2001). Most recently, an ambitious
AR100 VEGF expression and nontransgenic VEGF ex- analysis of patients with amyotrophic lateral sclerosis
pression. However, as the VEGF 164 isoform may pos- (ALS) has found that certain haplotypes in the VEGF
sess neuroprotective properties (Oosthuyse et al., 2001), gene are strongly associated with an increased likeli-
VEGF 164 seemed the most likely candidate. To assay hood of developing ALS (Lambrechts et al., 2003). The
VEGF 164, we designed a TaqMan probe and PCR prim- suspect VEGF haplotypes contain promoter variants
ers that specifically detect this isoform and observed that apparently decrease VEGF transcription. Our study
significant reductions in the RNA expression level of of the SBMA YAC mouse model offers yet another path-
VEGF 164 in AR100 mice in comparison to controls. way to motor neuron demise involving VEGF. We found
Importantly, a reduction, approximating that observed that polyglutamine-expanded AR can interfere with CBP
in the VEGF HRE-deleted mice (Oosthuyse et al., 2001) based upon an altered binding interaction and observed
was noted in AR100 mice as early as 6.5 months of age, marked decreases in VEGF expression in the spinal
long before they develop neurogenic muscle atrophy. cords of presymptomatic SBMA mice. While additional
Furthermore, no such VEGF 164 reduction was seen in transcription alterations are likely present in AR100
the spinal cords of SCA7 transgenic mice that express mice, the VEGF downregulation implicates impaired
mutant ataxin-7 in motor neurons (Garden et al., 2002). VEGF gene expression in SBMA motor neuron degener-
To confirm that reduction of VEGF 164 also occurs at ation. Thus, in the case of ALS and SBMA, two distinct
the protein level, we performed a VEGF ELISA assay on motor neuron diseases, the ability of the motor neuron
spinal cord lysates from 8-month-old AR100 mice and to adapt to cellular stress and injury may rest upon
detected a significant reduction in VEGF 120  164. the ability to fully activate VEGF gene expression. Our
While the ELISA assay detects both the 120 and 164 results, together with previous studies in mice and in
isoforms, most of the AR100 reduction likely reflects a humans, suggest that VEGF may play a pivotal role in
drop in VEGF 164, as AR20 VEGF 120  164 protein motor neuron degeneration. As no meaningful therapies
levels and AR20 VEGF RNA levels for all isoforms are exist for motor neuron diseases, an important goal will
elevated. AR20 VEGF 164 RNA levels, however, differ be to determine if VEGF delivery to motor neurons in
little from nontransgenic controls. our SBMA mouse model and in the ALS mouse model
The finding of VEGF downregulation in presymptom- can retard progression of motor neuron degeneration
atic AR100 mice led us to address two key questions. or possibly even reverse it.
(1) Is VEGF reduction biologically relevant to AR polyglu-
tamine neurotoxicity? (2) Does CBP transcription inter- Experimental Procedures
ference account for the VEGF downregulation induced
Transgenic Constructsby polyglutamine-expanded AR? To obtain answers to
A 450 kb YAC containing the human AR gene was obtained from athese questions, we evaluated the ability of VEGF and
CEPH human genomic YAC library and was characterized as de-CBP to rescue AR polyglutamine length-dependent neu-
scribed (La Spada et al., 1998). The generation and characterizationrotoxicity in a motor neuron-like cell culture system
of AR YAC CAG100 have been published (Sopher et al., 2000).
(MN-1 cells) (Salazar-Grueso et al., 1991). Using MN-1
cell viability as an endpoint, we tested whether VEGF Production and Characterization of Transgenic Mice
164 supplementation of the culture media could rescue To introduce intact 450 kb AR YACs into mice, we adopted the
AR112-induced cell death. We observed a dramatic res- method of yeast-embryonic stem (ES) cell fusion (Jakobovits et al.,
1993). R1 129X1/SvJ ES cells carrying an integrated AR YAC werecue by VEGF 164 supplementation and documented a
selected based upon resistance to G418. After verifying expression,dose response to increasing VEGF concentrations. To
R1 129X1/SvJ ES cells carrying integrated AR YACs were injectedevaluate the role of CBP transcription interference in
at the blastocyst stage into C57BL/6J embryos. Male chimeras withmutant AR-mediated VEGF transcription suppression,
regions of agouti coat color were then bred with C57BL/6J females
we overexpressed CBP in AR112-expressing MN-1 cells to create independent lines. Transgene-positive mice were then
and noted a significant increase in VEGF 164 by real- continually backcrossed onto the C57BL/6J strain background.
time RT-PCR. This finding strongly supported our model
of CBP transcription interference at the VEGF promoter, Reverse-Transcriptase PCR
RNA was isolated from transgenic mouse cortex by homogenizingas the recovery of VEGF expression was achieved at
in Trizol (Life Technologies). Total RNA (800 ng) was reverse tran-the VEGF promoter itself in the context of normal chro-
scribed using random hexamers and Superscript II (Life Technolo-matinized DNA instead of being linked to a reporter
gies). PCR primers (5-GGCTACACTCGGCCCCCTCAGGGGCTG-3
construct. CBP overexpression was thus sufficient to and 5-CCCTTCAGCGGCTCTTTTGAAGAAGAC-3) were designed
rescue AR polyglutamine neurotoxicity in the MN-1 to coamplify human and mouse cDNA sequences. After an initial
cell model. “hot start” at 98C for 2 min, 34 amplification cycles (94C for 30 s,
65C for 30 s, 72 for 30 s) with 2 Ci of dCTP –(	-33P) (3000Ci/mM;A critical issue in the motor neuron disease field is
Androgen Receptor YAC SBMA Mice with Altered VEGF
697
NEN) per reaction were performed. Samples were incubated with ELISA Assay
Total protein lysates were obtained by homogenizing tissues on iceApaI, a restriction enzyme that selectively digests the human am-
plicon. in extraction buffer (10 mM Sodium phosphate buffer [dibasic, ph
7.2], 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% Deoxycholic
acid, 0.2% Na azide, 0.0005 g/mL complete protease inhibitor
Western Blot Analysis [Boehringer Mannheim]) at a ratio of 1:15 (w/v). Lysates were incu-
Protein lysates were obtained by homogenizing tissues or PBS- bated on ice for 15 min and centrifuged at 4C at 14,000 rpm for 10
washed HEK-293T cell pellets in sample buffer (160 mM Tris-HCl min, diluted 1:3 in extraction buffer, and then assayed using the
[ph 6.9], 4% SDS, 200 mM dithiothreitol, 20% glycerol, 0.004% VEGF ELISA kit (Quantikine M, R&D Systems). Results were com-
Bromophenol blue) at a ratio of 1:10–1:20 (w/v). Protein samples pared by ANOVA with a post-hoc Tukey HSD test.
were immunoblotted as previously described (La Spada et al., 2001)
and probed with AR antibody H-280 or N-20 (Santa Cruz Biotechnol- MN-1 Rescue Experiments
ogy) at a 1:1000 dilution. 4 
 104 MN-1 cells were plated in DMEM with 10% FCS and DHT.
Cells were transfected with 0.2 g pcDNA3.1-AR (or empty vector)
cDNA and Lipofectamine 2000 (Invitrogen). Equivalent expressionBehavioral Analysis
of AR protein was confirmed by Western blot analysis. Twenty-fourFootprint analysis was performed as previously described (Taylor
hours after transfection, cells were treated for 48 hr with vehicleet al., 2001). Briefly, we constructed a 70 cm long tunnel, lined the
control or varying doses of recombinant mouse VEGF164 (2.5–50bottom with Whatman filter paper, placed mice in one end, and then
ng/ml) (R&D Systems). In the case of the CBP rescue experiments,sealed the entrance. A blinded investigator measured stride lengths
different amounts of CBP expression vector (pcDNA3.1-CBP [Kwokfrom two runs per individual. For the hanging wire strength test, we
et al., 1994]) was cotransfected with pcDNA3.1-AR112 and Lipofec-placed mice on a cage lid and then inverted them (Crawley, 1999).
tamine 2000. Viability was measured using the Live/Dead assayTests were performed on groups of six to eight individuals, and
(Molecular Probes). Data are representative of five experiments,results were compared by ANOVA (Microsoft EXCEL, Office ’98).
with all samples measured in triplicate. Statistical significance was
determined by Student’s t test or ANOVA.
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